Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE with Durvalumab or Durvalumab plus Bevacizumab in Locoregional Hepatocellular Carcinoma
2018-002134-20Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Mar 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing TACE + placebo, TACE + durvalumab and TACE + durvalumab + bevacizumab (3 arms). Primary endpoint: Progression Free Survival. Started Mar 2019; status: active.
02
Drugs
durvalumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2018-002134-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002134-20.